Buyout Of Questcor – Law Firm Seeks Higher Price For Shareholders

April 7, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Questcor Pharmaceuticals, Inc. on behalf of its shareholders. Mallinckrodt plc (MNK) and Questcor Pharmaceuticals, Inc. (QCOR) announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. Under the terms of the transaction, Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share.

The investigation concerns whether the board of directors of Questcor breached their fiduciary duties by not engaging in a full and fair auction and process to sell the company for the highest price possible to its shareholders. Indeed, analysts have projected that the true going forward inherent value of the company is worth at least $99 per share.

If you are a shareholder of Questcor and would like additional information regarding this matter and how you can participate with other shareholders seeking a higher price at no cost or expense, please contact us toll free at 1-877-772-3975 or contact us via our website.

Tripp Levy PLLC and its affiliates represents individual and institutional shareholders and have recovered billions of dollars for shareholders around the globe.